{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:19:05Z","timestamp":1768288745070,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Extramedullary disease in multiple myeloma often portends a worse diagnosis. In approximately 1% of cases, multiple myeloma may metastasize to the central nervous system as either leptomeningeal involvement or an intracranial, intraparenchymal lesion. Spinal cord metastases, however, are exceedingly rare. We present a case of spinal cord multiple myeloma as well as a literature review of reported cases.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 66-year-old African American man with multiple myeloma presented with acute midthoracic pain and lower extremity paresis and paresthesia. Magnetic resonance imaging of the spine revealed two contrast-enhancing intramedullary enhancing lesions in the T1\u2013T2 and T6\u2013T7 cord. Resection with biopsy yielded a diagnosis of metastatic multiple myeloma.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>To date, only six cases of extramedullary disease to the spinal cord in patients with multiple myeloma have been reported, including our patient\u2019s case. In all cases, neurologic deficit was observed at presentation, and magnetic resonance imaging of the spine revealed an intramedullary, homogeneously enhancing lesion. Current evidence suggests worse prognosis in patients with extramedullary disease to the central nervous system, and treatment paradigms remain debatable.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02496-5","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T23:06:45Z","timestamp":1602803205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multiple myeloma presenting as an intramedullary spinal cord tumor: a case report and\u00a0review of the literature"],"prefix":"10.1186","volume":"14","author":[{"given":"Long","family":"Di","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigran","family":"Kesayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Macaulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"6","key":"2496_CR1","first-page":"373","volume":"95","author":"TC Michels","year":"2017","unstructured":"Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017;95(6):373\u201383.","journal-title":"Am Fam Physician"},{"issue":"2","key":"2496_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360\u20134.","journal-title":"Haematologica"},{"issue":"9","key":"2496_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/archneur.61.9.1423","volume":"61","author":"KO Schluterman","year":"2004","unstructured":"Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. Arch Neurol. 2004;61(9):1423\u20139.","journal-title":"Arch Neurol"},{"issue":"6","key":"2496_CR4","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/cncr.26447","volume":"118","author":"A Gozzetti","year":"2012","unstructured":"Gozzetti A, Cerase A, Lotti F, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118(6):1574\u201384.","journal-title":"Cancer"},{"issue":"4","key":"2496_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/ajcp\/78.4.532","volume":"78","author":"LD Truong","year":"1982","unstructured":"Truong LD, Kim HS, Estrada R. Meningeal myeloma. Am J Clin Pathol. 1982;78(4):532\u20135.","journal-title":"Am J Clin Pathol"},{"issue":"9983","key":"2496_CR6","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2015","unstructured":"Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385(9983):2197\u2013208.","journal-title":"Lancet"},{"issue":"1","key":"2496_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","volume":"154","author":"JM Bird","year":"2011","unstructured":"Bird JM, Owen RG, D\u2019Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154(1):32\u201375.","journal-title":"Br J Haematol"},{"issue":"Suppl 4","key":"2496_CR8","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv52\u201361.","journal-title":"Ann Oncol"},{"issue":"1","key":"2496_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"2496_CR10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","volume":"27","author":"A Riccardi","year":"1991","unstructured":"Riccardi A, Gobbi PG, Ucci G, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer. 1991;27(11):1401\u20135.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2496_CR11","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.4081\/hr.2017.6887","volume":"9","author":"A Nakaya","year":"2017","unstructured":"Nakaya A, Fujita S, Satake A, et al. Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era. Hematol Rep. 2017;9(1):6887.","journal-title":"Hematol Rep"},{"issue":"2","key":"2496_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325\u201330.","journal-title":"Ann Oncol"},{"issue":"2","key":"2496_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/10428190802657751","volume":"50","author":"P Wu","year":"2009","unstructured":"Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230\u20135.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2496_CR14","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","volume":"12","author":"J Blade","year":"1994","unstructured":"Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398\u2013404.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2496_CR15","first-page":"3141","volume":"122","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV, Dispenzieri A, Lacy MQ, et al. Incidence and survival outcomes of extramedullary myeloma [abstract]. Blood. 2013;122(21):3141.","journal-title":"Blood"},{"issue":"2","key":"2496_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","volume":"93","author":"J Blade","year":"1996","unstructured":"Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93(2):345\u201351.","journal-title":"Br J Haematol"},{"issue":"7 Suppl","key":"2496_CR17","first-page":"P07.005","volume":"80","author":"N Majd","year":"2013","unstructured":"Majd N, Demopoulos A, Chari A. Central nervous system involvement in multiple myeloma patients in the era of novel therapies [abstract P07.005]. Neurology. 2013;80(7 Suppl):P07.005.","journal-title":"Neurology"},{"issue":"1","key":"2496_CR18","first-page":"30","volume":"40","author":"A Dias","year":"2018","unstructured":"Dias A, Higashi F, Peres ALM, Cury P, Crusoe EQ, Hungria VTM. Multiple myeloma and central nervous system involvement: experience of a Brazilian center. Rev Bras Hematol Hemoter. 2018;40(1):30\u20136.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"11","key":"2496_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.clml.2016.08.010","volume":"16","author":"J Paludo","year":"2016","unstructured":"Paludo J, Painuly U, Kumar S, et al. Myelomatous involvement of the central nervous system. Clin Lymphoma Myeloma Leuk. 2016;16(11):644\u201354.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2496_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/ajh.24351","volume":"91","author":"A Jurczyszyn","year":"2016","unstructured":"Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91(6):575\u201380.","journal-title":"Am J Hematol"},{"issue":"4","key":"2496_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bjh.12414","volume":"162","author":"CI Chen","year":"2013","unstructured":"Chen CI, Masih-Khan E, Jiang H, et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013;162(4):483\u20138.","journal-title":"Br J Haematol"},{"issue":"3","key":"2496_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.clml.2013.11.004","volume":"14","author":"AO Abdallah","year":"2014","unstructured":"Abdallah AO, Atrash S, Shahid Z, et al. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14(3):211\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2496_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03401.x","volume":"117","author":"AB Fassas","year":"2002","unstructured":"Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117(1):103\u20138.","journal-title":"Br J Haematol"},{"issue":"11","key":"2496_CR24","first-page":"1402","volume":"123","author":"XY Qu","year":"2010","unstructured":"Qu XY, Fu WJ, Xi H, Zhou F, Wei W, Hou J. Clinical features of multiple myeloma invasion of the central nervous system in Chinese patients. Chin Med J. 2010;123(11):1402\u20136.","journal-title":"Chin Med J"},{"issue":"2","key":"2496_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00330-017-5023-5","volume":"28","author":"F Stacul","year":"2018","unstructured":"Stacul F, Bertolotto M, Thomsen HS, et al. Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2018;28(2):683\u201391.","journal-title":"Eur Radiol"},{"issue":"7","key":"2496_CR26","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/1097-0142(19921001)70:7<1899::AID-CNCR2820700716>3.0.CO;2-3","volume":"70","author":"D Leifer","year":"1992","unstructured":"Leifer D, Grabowski T, Simonian N, Demirjian ZN. Leptomeningeal myelomatosis presenting with mental status changes and other neurologic findings. Cancer. 1992;70(7):1899\u2013904.","journal-title":"Cancer"},{"issue":"3","key":"2496_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/1097-0142(197303)31:3<520::AID-CNCR2820310306>3.0.CO;2-2","volume":"31","author":"RA Price","year":"1973","unstructured":"Price RA, Johnson WW. The central nervous system in childhood leukemia. I. The arachnoid. Cancer. 1973;31(3):520\u201333.","journal-title":"Cancer"},{"issue":"1","key":"2496_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","volume":"81","author":"A Neri","year":"1993","unstructured":"Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81(1):128\u201335.","journal-title":"Blood"},{"issue":"3","key":"2496_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2141.2004.05199.x","volume":"127","author":"H Chang","year":"2004","unstructured":"Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280\u20134.","journal-title":"Br J Haematol"},{"issue":"8","key":"2496_CR30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971\u20136.","journal-title":"Blood"},{"issue":"4","key":"2496_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","volume":"69","author":"JA Muscal","year":"2012","unstructured":"Muscal JA, Sun Y, Nuchtern JG, et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol. 2012;69(4):943\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2496_CR32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/ejh.12247","volume":"92","author":"H Nahi","year":"2014","unstructured":"Nahi H, Svedmyr E, Lerner R. Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement. Eur J Haematol. 2014;92(5):454\u20135.","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"2496_CR33","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1182\/blood-2018-99-117203","volume":"132","author":"MC Da Via","year":"2018","unstructured":"Da Via MC, Solimando AG, et al. CIC-mutation as a potential molecular mechanism of acquired resistance to combined BRAF\/MEK inhibition in CNS multiple myeloma [abstract]. Blood. 2018;132(Suppl 1):3181.","journal-title":"Blood"},{"issue":"4","key":"2496_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<228::AID-AJH5>3.0.CO;2-3","volume":"62","author":"SL Petersen","year":"1999","unstructured":"Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation: a case report and review of the literature. Am J Hematol. 1999;62(4):228\u201333.","journal-title":"Am J Hematol"},{"issue":"4","key":"2496_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/hon.1021","volume":"30","author":"SA Gangatharan","year":"2012","unstructured":"Gangatharan SA, Carney DA, Prince HM, et al. Emergence of central nervous system myeloma in the era of novel agents. Hematol Oncol. 2012;30(4):170\u20134.","journal-title":"Hematol Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-020-02496-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T06:09:24Z","timestamp":1634364564000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02496-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02496-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report did not constitute human subjects research, and thus institutional review board approval was not sought or required. All patient information was de-identified in accordance with Health Insurance Portability and Accountability Act guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We affirm that the material in this report has not been published and is not being considered for publication elsewhere, either in whole or in part. Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}